Amitriptyline HCL Tablets   2

Background
The solicitation is issued by the Department of Veterans Affairs (VA) and the Department of Defense (DoD) for the acquisition of pharmaceutical products through their respective Pharmaceutical Prime Vendor (PPV) Programs. The purpose is to establish a supply source that will provide drugs listed in the schedule for purchase through the PPV Programs, ensuring availability and consistency of product for nationwide usage and obtaining volume-based, committed-use pricing.

Work Details
The contract is for the supply of Amitriptyline HCL Tablets. The solicitation requires offerors to submit a price for all line items offered, inclusive of the base year and all option years. Offered prices must include a 0.5% Cost Recovery Fee. The contract will have an Implementation Period and an Ordering Period, with specific timeframes for each. The contractor will be receiving payments from the PPV programs instead of directly from the government agency. The solicitation also includes detailed instructions for proposal submission, including requirements for Unique Entity Identifier, National Drug Code (NDC) Number, packaging, and registration.

Period of Performance
The contract award/effective date is 05-25-2023, with an offer due date/local time of 06-09-2023 at 2:30 PM CT. The Implementation Period will be a maximum of 60 calendar days, and the base year Ordering Period will be in effect for one year.

Place of Performance
The products will be delivered to various facilities/agencies including all VA facilities, all DoD Pharmaceutical Prime Vendor Program facilities, Indian Health Service facilities, Bureau of Prisons facilities, Captain James A. Lovell Federal Health Care Center, and State Veteran Homes.